Amylyx Pharmaceuticals.
American biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 34
What's happening
Earlier this month
One to three months ago
-
Amylyx Pharmaceuticals shares surged following the announcement of successful clinical trial results.Some support1 report
-
Avexitide received FDA Breakthrough Therapy designation.Well supported5 reports1 development inside
-
Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.Some support3 reports
-
Amylyx Pharmaceuticals listed its stock on Nasdaq and filed reports with the Securities and Exchange Commission.Some support2 reports
Gone quiet
No new reports in 90+ days-
Market sentiment shifts affect stock valuations for Amylyx Pharmaceuticals and DoorDash.Some support1 report
-
Amylyx Pharmaceuticals appoints George Milne to the board, Joshua Cohen as co-CEO, and ratifies Deloitte & Touche as its auditor.Some support1 report
-
Amylyx Pharmaceuticals received a Buy rating on its stock, noting that the company benefits from Trump-era tariffs and onshoring trends.Some support2 reports
-
FDA granted Fast Track designation to AMX0114, a treatment related to Amylyx Pharmaceuticals' mission.Speculative1 report
-
Amylyx Pharmaceuticals and Netflix were mentioned in the context of high stock returns on June 27, 2025.Speculative1 report
-
Amylyx Pharmaceuticals received FDA Fast Track designation on August 7, 2025, for treatments aimed at ALS, including evaluating avexitide post-RYGB surgery.Some support3 reports2 developments inside
-
Amylyx Pharmaceuticals used LinkedIn for investor communication and its management participated in conferences held in New York City and Boston on August 26, 2025.Some support2 reports
-
The pharmaceutical industry is seeing developments in ALS drug treatment, including partnerships and drug approvals involving major companies.Some support1 report
-
Amylyx Pharmaceuticals previously treated ALS using AMX0035 and gained approval in Canada.Some support1 report
-
Amylyx Pharmaceuticals and Phoenix are continuing development of AMX0114 and conducting the PHOENIX Phase 3 trial for ALS.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Amylyx Pharmaceuticals this week
News at the entities that move Amylyx Pharmaceuticals most-
FDA StructuralFDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.Moves Amylyx Pharmaceuticals
-
Securities and Exchange Commission StructuralThe executive chairman and CEO of NeOnc filed Form 4 filings with the Securities and Exchange Commission.Moves Amylyx Pharmaceuticals
-
LinkedIn OperationalA judge wrote an opinion on LinkedIn disclosure following a leak investigation initiated by the Trump administration.Moves Amylyx Pharmaceuticals
-
Citigroup Mentioned togetherCantor Fitzgerald and Citigroup restated positive rating upgrades for Sagimet Biosciences.Moves Amylyx Pharmaceuticals
-
MarketBeat Mentioned togetherMarketBeat provided analyst recommendations comparing materials companies Barrick Mining and Salzgitter.Moves Amylyx Pharmaceuticals
-
Benzinga Mentioned togetherSkydance Media received an overweight rating and a price objective raise, as reported by Benzinga and Cantor Fitzgerald.Moves Amylyx Pharmaceuticals
Connections
The 16 strongest of 34, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Amylyx Pharmaceuticals is subject to the formal regulatory review and approval process of the FDA for its drug candidates.
-
Joshua Cohen Structural
Joshua Cohen serves as co-chief executive officer of Amylyx Pharmaceuticals.
-
George Milne Structural
George Milne serves as a board member of Amylyx Pharmaceuticals.
-
Securities and Exchange Commission Structural
The company must comply with the rules and oversight of the Securities and Exchange Commission.
-
LinkedIn Operational
Amylyx Pharmaceuticals actively uses LinkedIn as a platform for company and investor communications.
-
Citigroup Mentioned together
Citigroup provides financial analysis, including buy ratings and price targets, for Amylyx Pharmaceuticals.
-
Benzinga Mentioned together
Benzinga tracks and reports on Amylyx Pharmaceuticals' stock performance and market news.
-
DoorDash Mentioned together
Both companies are mentioned in the context of how market sentiment affects stock valuations.
Show all 16 connections
-
New York City Shared context
Amylyx Pharmaceuticals operates and participates in conferences held within New York City.
-
Deloitte & Touche LLP Structural
Amylyx Pharmaceuticals relies on Deloitte & Touche LLP for formal auditing services, a role ratified by its stockholders.
-
Mizuho Mentioned together
Mizuho analysts have increased their target price for Amylyx Pharmaceuticals.
-
Nasdaq Shared context
Amylyx Pharmaceuticals is a company whose stock is listed on the Nasdaq stock exchange.
-
ASIC Mentioned together
The available evidence is too generic to define a specific relationship between the two entities.
-
MarketBeat Mentioned together
MarketBeat provides financial data and consensus ratings regarding Amylyx Pharmaceuticals.
-
FactSet Mentioned together
No direct relationship between Amylyx Pharmaceuticals and FactSet was observed in the provided evidence.
-
Als Mentioned together
Amylyx Pharmaceuticals' activities regarding ALS are documented, but no direct relationship with Als is observed in the evidence.
History
Events by the month they beganAugust 2026
4 events- Amylyx Pharmaceuticals shares surged following the announcement of successful clinical trial results.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Amylyx Pharmaceuticals listed its stock on Nasdaq and filed reports with the Securities and Exchange Commission.
- Market sentiment shifts affect stock valuations for Amylyx Pharmaceuticals and DoorDash.
July 2026
1 eventJune 2026
10 events- Avexitide received FDA Breakthrough Therapy designation.
- Amylyx Pharmaceuticals appoints George Milne to the board, Joshua Cohen as co-CEO, and ratifies Deloitte & Touche as its auditor.
- Amylyx Pharmaceuticals received a Buy rating on its stock, noting that the company benefits from Trump-era tariffs and onshoring trends.
- FDA granted Fast Track designation to AMX0114, a treatment related to Amylyx Pharmaceuticals' mission.
- Amylyx Pharmaceuticals and Netflix were mentioned in the context of high stock returns on June 27, 2025.
- Amylyx Pharmaceuticals received FDA Fast Track designation on August 7, 2025, for treatments aimed at ALS, including evaluating avexitide post-RYGB surgery.
- Amylyx Pharmaceuticals used LinkedIn for investor communication and its management participated in conferences held in New York City and Boston on August 26, 2025.
- The pharmaceutical industry is seeing developments in ALS drug treatment, including partnerships and drug approvals involving major companies.
- Amylyx Pharmaceuticals previously treated ALS using AMX0035 and gained approval in Canada.
- Amylyx Pharmaceuticals and Phoenix are continuing development of AMX0114 and conducting the PHOENIX Phase 3 trial for ALS.